FDA Files Lawsuit Against Six E-Cigarette Companies for Illegal Operations

Regulations by 2FIRSTS.ai
Apr.28.2024
FDA Files Lawsuit Against Six E-Cigarette Companies for Illegal Operations
The U.S. federal government sues six e-cigarette companies, including one in Columbus, for illegal production and sale of nicotine products.

According to a report by AOL on April 27, the US federal government filed a lawsuit on Tuesday (23rd) against six e-cigarette companies (one of which is located in Columbus), accusing them or related individuals of illegally producing and selling electronic nicotine delivery system products.

 

Brian King, director of the Center for Tobacco Products at the Food and Drug Administration (FDA), said, "Today's enforcement action represents a significant step by the FDA to prevent tobacco product manufacturers from breaking the law."

 

The lawsuit alleges that these companies have been producing and selling "e-cigarette nicotine delivery systems" without authorization from the FDA. Despite receiving notices requiring FDA authorization, these companies continued to act illegally. One of the Columbus-based companies mentioned in the lawsuit is Vapor Craft LLC, owned by Melissa D. Anderson.

 

Attorney Todd Swanson will represent the US government in court, Judge Clay Land will preside over the case.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.
Feb.03 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
A new report from Cancer Council’s Generation Vape research project shows that fewer teenagers in New South Wales are trying vaping after the state government introduced tougher vaping goods laws. Among surveyed NSW teenagers aged 14 to 17, the proportion who had tried vaping fell from 29.6% in April 2024 to 20.1% in October 2025.
Mar.17 by 2FIRSTS.ai
Make Your Brand Understood by the People Who Matter
Make Your Brand Understood by the People Who Matter
Feb.02
Philippine Lawmakers Push Bill to Close Vape Tax Loopholes
Philippine Lawmakers Push Bill to Close Vape Tax Loopholes
Lawmakers in the Philippines are pushing House Bill 5207 (HB 5207), which seeks to harmonize excise tax rates on vapor products and address disparities between nicotine salt and freebase nicotine taxation. The bill, supported by more than 40 lawmakers including Deputy Speaker Kristine Singson-Meehan, would raise taxes on freebase nicotine products to align them with nicotine salt rates.
Regulations
Feb.22
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12